- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANO HEALTH Aktie jetzt für 0€ handeln | |||||
| 20.10. | Ex-Cano Health CEO on Trial Amid $72M Fraud Claims | 2 | MedCity News |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 282,90 | +2,19 % | Wichtige Termine! LVMH, UnitedHealth, Meta, Strategy, Bitcoin im Check | Die Aktienmärkte haben eine schwache Handelswoche hinter sich. Sowohl der DAX als auch die großen US-Indizes gaben in der vergangenen Woche deutlich ab. Immerhin macht die Wall Street mit ihrer Performance... ► Artikel lesen | |
| INTUITIVE SURGICAL | 501,40 | +1,65 % | ISRG vs. MDT: A High-Tech Robotics Faceoff in the Race for Leadership | ||
| THERMO FISHER | 513,60 | +0,98 % | Thermo Fisher Scientific Subsidiary Prices EUR 2.1 Bln Senior Notes Offering | HONG KONG (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) has priced an offering of 2.1 billion euros aggregate principal amount of euro-denominated notes, to be issued by Thermo Fisher Scientific... ► Artikel lesen | |
| ROKU | 81,96 | +0,94 % | Access Advance Applauds Historic Preliminary Injunction in German HEVC Enforcement Action Against Roku | BOSTON, MA / ACCESS Newswire / November 24, 2025 / Access Advance LLC today announced that one of its Licensors, Dolby International AB, has obtained a historic preliminary injunction from the Landgericht... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,641 | -2,14 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 34,175 | +3,15 % | Why Centene Stock Just Popped | ||
| QUIDELORTHO | 24,000 | +3,45 % | QuidelOrtho Corporation: QuidelOrtho Reports Third Quarter 2025 Financial Results | ? Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ? ... ► Artikel lesen | |
| VERU | 2,420 | +3,42 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 | All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR- Antagonist, Phase 3-ready) and TPST-1495... ► Artikel lesen | |
| NANO-X IMAGING | 4,505 | +8,95 % | NANO-X IMAGING LTD: Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System | Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's... ► Artikel lesen | |
| FULGENT GENETICS | 26,600 | 0,00 % | Raymond James erhöht Kursziel für Fulgent Genetics nach starken Zahlen auf 36 US-Dollar | ||
| LANTHEUS | 50,96 | +3,92 % | Lantheus Holdings, Inc.: Lantheus to Present Florbetaben F 18 Data at CTAD 2025 | ||
| PERSPECTIVE THERAPEUTICS | 2,020 | +7,45 % | UBS lowers Perspective Therapeutics stock price target on competition concerns | ||
| AMN HEALTHCARE SERVICES | 14,100 | +2,17 % | AMN Healthcare Services Inc: AMN Healthcare Announces Third Quarter 2025 Results | Quarterly revenue of $634 million and adjusted EBITDA of $58 million; GAAP income of $0.76/share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:... ► Artikel lesen |
CANO HEALTH INC gehört der Branche Gesundheitswesen an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANO HEALTH INC finden Sie auf Wallstreet Online.